PDGFRA and glioblastoma: To test the impact of pharmacologically targeting the HIF1α-PDGFD-PDGFRα axis in GBM in vivo, we took advantage of an improved formulation of Echinomycin which we developed recently using liposomes (LEM) to treat solid tumors [44, 45].